Pharmacodynamics for antifungal drug development: an approach for acceleration, risk minimization and demonstration of causality.

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Journal of Antimicrobial Chemotherapy

• Publication date

  2016-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1093/JAC/DKW298PMID 27494925
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Pharmacodynamics of Amphotericin B Deoxycholate, Amphotericin B Lipid Complex, and Liposomal Amphotericin B against Aspergillus fumigatus

  2015cited by this paper
• Pharmacodynamics of Isavuconazole in a Dynamic In Vitro Model of Invasive Pulmonary Aspergillosis

  2015cited by this paper
• Pharmacodynamics of Isavuconazole in an Aspergillus fumigatus Mouse Infection Model

  2015cited by this paper
• Intermittent Dosing of Micafungin Is Effective for Treatment of Experimental Disseminated Candidiasis in Persistently Neutropenic Rabbits.

  2015cited by this paper
• Efficacy of an Abbreviated Induction Regimen of Amphotericin B Deoxycholate for Cryptococcal Meningoencephalitis: 3 Days of Therapy Is Equivalent to 14 Days

  2014cited by this paper
• Tissue Penetration of Antifungal Agents

  2014cited by this paper
• EUCAST technical note on voriconazole and Aspergillus spp.

  2013cited by this paper
• Isavuconazole (BAL4815) Pharmacodynamic Target Determination in an In Vivo Murine Model of Invasive Pulmonary Aspergillosis against Wild-Type and cyp51 Mutant Isolates of Aspergillus fumigatus

  2013cited by this paper
• Pharmacokinetics and Pharmacodynamics of Fluconazole for Cryptococcal Meningoencephalitis: Implications for Antifungal Therapy and In Vitro Susceptibility Breakpoints

  2013cited by this paper
• Pharmacodynamics of liposomal amphotericin B and flucytosine for cryptococcal meningoencephalitis: safe and effective regimens for immunocompromised patients.

  2013cited by this paper
• Itraconazole: an update on pharmacology and clinical use for treatment of invasive and allergic fungal infections

  2013cited by this paper
• In Vitro Interaction of Voriconazole and Anidulafungin against Triazole-Resistant Aspergillus fumigatus

  2012cited by this paper
• EUCAST technical note on the EUCAST definitive document EDef 7.2: method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for yeasts EDef 7.2 (EUCAST-AFST).

  2012cited by this paper
• Pharmacokinetics and Pharmacodynamics of Anidulafungin for Experimental Candida Endophthalmitis: Insights into the Utility of Echinocandins for Treatment of a Potentially Sight-Threatening Infection

  2012cited by this paper
• Differential In Vivo Activities of Anidulafungin, Caspofungin, and Micafungin against Candida glabrata Isolates with and without FKS Resistance Mutations

  2012cited by this paper
• Posaconazole Pharmacodynamic Target Determination against Wild-Type and Cyp51 Mutant Isolates of Aspergillus fumigatus in an In Vivo Model of Invasive Pulmonary Aspergillosis

  2012cited by this paper
• Pharmacodynamics of Anidulafungin against Clinical Aspergillus fumigatus Isolates in a Nonneutropenic Murine Model of Disseminated Aspergillosis

  2012cited by this paper
• Pulmonary Aspergillosis: Implications for In Vitro Susceptibility Breakpoints

  2012cited by this paper
• Caspofungin Dose Escalation for Invasive Candidiasis Due to Resistant Candida albicans

  2011cited by this paper
• Observational Study of the Clinical Efficacy of Voriconazole and Its Relationship to Plasma Concentrations in Patients

  2011cited by this paper
• Pharmacokinetics and pharmacodynamics of posaconazole for invasive pulmonary aspergillosis: clinical implications for antifungal therapy.

  2011cited by this paper
• Pharmacodynamics of Echinocandins against Candida glabrata: Requirement for Dosage Escalation To Achieve Maximal Antifungal Activity in Neutropenic Hosts

  2011cited by this paper
• Pharmacodynamic Effects of Simulated Standard Doses of Antifungal Drugs against Aspergillus Species in a New In Vitro Pharmacokinetic/Pharmacodynamic Model

  2011cited by this paper
• Anidulafungin for Neonatal Hematogenous Candida Meningoencephalitis: Identification of Candidate Regimens for Humans Using a Translational Pharmacological Approach

  2011cited by this paper
• Disseminated Candidiasis Caused by Candida albicans with Amino Acid Substitutions in Fks1 at Position Ser645 Cannot Be Successfully Treated with Micafungin

  2011cited by this paper
• Observational Study of the Clinical Efficacy of Voriconazole and Its Relationship to Plasma Concentrations in Patients

  2011cited by this paper
• Therapy for fungal diseases: opportunities and priorities.

  2010cited by this paper
• The Initial 96 Hours of Invasive Pulmonary Aspergillosis: Histopathology, Comparative Kinetics of Galactomannan and (1→3)-β-d-Glucan, and Consequences of Delayed Antifungal Therapy

  2010cited by this paper
• Efficacy of Posaconazole against Three Clinical Aspergillus fumigatus Isolates with Mutations in the cyp51A Gene

  2009cited by this paper
• Antifungal pharmacokinetics and pharmacodynamics: bridging from the bench to bedside.

  2009cited by this paper
• EUCAST DEFINITIVE DOCUMENT E.DEF 9.1: Method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for conidia forming moulds

  2008cited by this paper
• (1→3)-β-D-Glucan in Cereobrospinal Fluid is a Surrogate Marker for Detection and Therapeutic Response of Hematogenous Candida Meningoencephalitis

  2008cited by this paper
• In Vivo Pharmacodynamic Target Investigation for Micafungin against Candida albicans and C. glabrata in a Neutropenic Murine Candidiasis Model

  2008cited by this paper
• The pharmacokinetics and pharmacodynamics of micafungin in experimental hematogenous Candida meningoencephalitis: implications for echinocandin therapy in neonates.

  2008cited by this paper
• Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial).

  2007cited by this paper
• Pathogenesis of Aspergillus fumigatus and the kinetics of galactomannan in an in vitro model of early invasive pulmonary aspergillosis: implications for antifungal therapy.

  2007cited by this paper
• Derivation of an In Vivo Drug Exposure Breakpoint for Flucytosine against Candida albicans and Impact of the MIC, Growth Rate, and Resistance Genotype on the Antifungal Effect

  2006cited by this paper
• Pharmacodynamic Activity of Amphotericin B Deoxycholate Is Associated with Peak Plasma Concentrations in a Neutropenic Murine Model of Invasive Pulmonary Aspergillosis

  2006cited by this paper
• Standardization of an Experimental Murine Model of Invasive Pulmonary Aspergillosis

  2006cited by this paper
• Statistical characterisation of bacterial wild-type MIC value distributions and the determination of epidemiological cut-off values.

  2006cited by this paper
• Once-Weekly Micafungin Therapy Is as Effective as Daily Therapy for Disseminated Candidiasis in Mice with Persistent Neutropenia

  2006cited by this paper
• Effect of Neutropenia and Treatment Delay on the Response to Antifungal Agents in Experimental Disseminated Candidiasis

  2006cited by this paper
• Pharmacodynamics of Caspofungin in a Murine Model of Systemic Candidiasis: Importance of Persistence of Caspofungin in Tissues to Understanding Drug Activity

  2005cited by this paper
• Correspondence of In Vitro and In Vivo Fluconazole Dose-Response Curves for Cryptococcus neoformans

  2005cited by this paper
• Laboratory diagnosis of invasive aspergillosis.

  2005cited by this paper
• Novel Inhalational Murine Model of Invasive Pulmonary Aspergillosis

  2004cited by this paper
• Pharmacodynamics of a New Triazole, Posaconazole, in a Murine Model of Disseminated Candidiasis

  2004cited by this paper
• Antimicrobial pharmacodynamics: critical interactions of 'bug and drug'

  2004cited by this paper
• Pharmacodynamics of caspofungin in a murine model of invasive pulmonary aspergillosis: evidence of concentration-dependent activity.

  2004cited by this paper
• In Vivo Pharmacodynamics of HMR 3270, a Glucan Synthase Inhibitor, in a Murine Candidiasis Model

  2003cited by this paper
• Hypothesis: A single clinical trial plus causal evidence of effectiveness is sufficient for drug approval

  2003cited by this paper
• In Vivo Pharmacokinetics and Pharmacodynamics of a New Triazole, Voriconazole, in a Murine Candidiasis Model

  2003cited by this paper
• Safety, Tolerance, and Pharmacokinetics of High-Dose Liposomal Amphotericin B (AmBisome) in Patients Infected withAspergillus Species and Other Filamentous Fungi: Maximum Tolerated Dose Study

  2001cited by this paper
• In Vivo Characterization of the Pharmacodynamics of Flucytosine in a Neutropenic Murine Disseminated Candidiasis Model

  2000cited by this paper
• Characterization and Quantitation of the Pharmacodynamics of Fluconazole in a Neutropenic Murine Disseminated Candidiasis Infection Model

  1999cited by this paper
• Pharmacodynamics of Fluconazole in a Murine Model of Systemic Candidiasis

  1998cited by this paper
• An EORTC international multicenter randomized trial (EORTC number 19923) comparing two dosages of liposomal amphotericin B for treatment of invasive aspergillosis.

  1998cited by this paper
• Antifungal Efficacy, Safety, and Single-Dose Pharmacokinetics of LY303366, a Novel Echinocandin B, in Experimental Pulmonary Aspergillosis in Persistently Neutropenic Rabbits

  1998cited by this paper
• Effect of severity of meningitis on fungicidal activity of flucytosine combined with fluconazole in a murine model of cryptococcal meningitis

  1997cited by this paper
• Effect of fluconazole on fungicidal activity of flucytosine in murine cryptococcal meningitis

  1996cited by this paper
• Chronic cryptococcal meningitis: a new experimental model in rabbits.

  1980cited by this paper

• Impact of Fab1/Vac14 inhibition on β-1,3-glucanase localization at the tip in Saccharomyces cerevisiae.

  2024cites this paper
• Assessment of Antifungal Pharmacodynamics

  2023cites this paper
• Antibacterial properties of Monarda essential oils

  2022cites this paper
• Fighting Back against Antimicrobial Resistance with Comprehensive Policy and Education: A Narrative Review

  2022cites this paper
• Tackling the emerging threat of antifungal resistance to human health

  2022cites this paper
• Therapeutic Potential of Fosmanogepix (APX001) for Intra-abdominal Candidiasis: from Lesion Penetration to Efficacy in a Mouse Model

  2021cites this paper
• From bench to bedside: Perspectives on the utility of pharmacokinetics/pharmacodynamics in predicting the efficacy of antifungals in invasive candidiasis

  2020cites this paper
• Implications of Evolving and Emerging Pharmacokinetic-Pharmacodynamic Research for Triazoles and Echinocandins

  2020cites this paper
• The Lymphocytic Scavenger Receptor CD5 Shows Therapeutic Potential in Mouse Models of Fungal Infection

  2020cites this paper
• Optimal kinetic exposures for classic and candidate antitrypanosomals.

  2019cites this paper
• Extended Dosing Regimens for Fungal Prophylaxis

  2019cites this paper
• Exposure–Response Analysis of Micafungin in Neonatal Candidiasis

  2018cites this paper
• Pharmacodynamics of the Orotomides against Aspergillus fumigatus: New Opportunities for Treatment of Multidrug-Resistant Fungal Disease

  2017cites this paper
• Animal Models for Studying Triazole Resistance in Aspergillus fumigatus.

  2017cites this paper
• Prescribing Pattern of Antifungal Medications at a Tertiary Care Hospital in Oman.

  2016cites this paper